Last updated: 17 July 2019 at 7:48am EST

Kenneth Green Net Worth




The estimated Net Worth of Kenneth Green is at least $1.11 Million dollars as of 18 January 2018. Kenneth Green owns over 10,638 units of Alimera Sciences stock worth over $943,606 and over the last 14 years Kenneth sold ALIM stock worth over $170,697.

Kenneth Green ALIM stock SEC Form 4 insiders trading

Kenneth has made over 10 trades of the Alimera Sciences stock since 2011, according to the Form 4 filled with the SEC. Most recently Kenneth sold 10,638 units of ALIM stock worth $12,766 on 18 January 2018.

The largest trade Kenneth's ever made was exercising 73,529 units of Alimera Sciences stock on 11 February 2014 worth over $149,999. On average, Kenneth trades about 13,853 units every 110 days since 2010. As of 18 January 2018 Kenneth still owns at least 170,634 units of Alimera Sciences stock.

You can see the complete history of Kenneth Green stock trades at the bottom of the page.



What's Kenneth Green's mailing address?

Kenneth's mailing address filed with the SEC is 6120 WINDWARD PARKWAY, SUITE 290, , ALPHARETTA, GA, 30005.

Insiders trading at Alimera Sciences

Over the last 15 years, insiders at Alimera Sciences have traded over $14,704,529 worth of Alimera Sciences stock and bought 8,598,915 units worth $59,337,384 . The most active insiders traders include Capital, Llc Armistice Capi..., Nicole Vitullo, and Jesse I Treu. On average, Alimera Sciences executives and independent directors trade stock every 32 days with the average trade being worth of $468,137. The most recent stock trade was executed by Partners Lpjohnson David Ed... on 14 September 2023, trading 579,000 units of ALIM stock currently worth $1,962,810.



What does Alimera Sciences do?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.



What does Alimera Sciences's logo look like?

Alimera Sciences Inc. logo

Complete history of Kenneth Green stock trades at Alimera Sciences

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
18 Jan 2018 Kenneth Green
SVP and Chief Scientific Officer
Sale 10,638 $1.20 $12,766
18 Jan 2018
170,634
16 Jan 2018 Kenneth Green
SVP and Chief Scientific Officer
Sale 11,489 $1.23 $14,131
16 Jan 2018
181,272
11 Oct 2016 Kenneth Green
SVP and Chief Scientific Officer
Option 44,208 $1.33 $58,797
11 Oct 2016
136,561
16 Dec 2015 Kenneth Green
SVP and Chief Scientific Officer
Option 44,118 $1.33 $58,677
16 Dec 2015
92,353
16 Dec 2015 Kenneth Green
SVP and Chief Scientific Officer
Option 44,118 $1.33 $58,677
16 Dec 2015
92,353
21 Aug 2015 Kenneth Green
SVP and Chief Scientific Officer
Sale 20,000 $3.29 $65,800
21 Aug 2015
48,235
17 Aug 2015 Kenneth Green
SVP and Chief Scientific Officer
Sale 20,000 $3.90 $78,000
17 Aug 2015
68,235
9 Dec 2014 Kenneth Green
SVP and Chief Scientific Officer
Option 14,706 $2.04 $30,000
9 Dec 2014
88,235
11 Feb 2014 Kenneth Green
SVP and Chief Scientific Officer
Option 73,529 $2.04 $149,999
11 Feb 2014
73,529
7 Jun 2011 Kenneth Green
SVP and Chief Scientific Officer
Option 21,969 $1.33 $29,219
7 Jun 2011
21,969


Alimera Sciences executives and stock owners

Alimera Sciences executives and other stock owners filed with the SEC include: